1. Home
  2. AMBO vs ERNA Comparison

AMBO vs ERNA Comparison

Compare AMBO & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ambow Education Holding Ltd.

AMBO

Ambow Education Holding Ltd.

HOLD

Current Price

$2.30

Market Cap

6.5M

Sector

Real Estate

ML Signal

HOLD

Logo Eterna Therapeutics Inc.

ERNA

Eterna Therapeutics Inc.

HOLD

Current Price

$7.40

Market Cap

5.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMBO
ERNA
Founded
2000
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
5.8M
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
AMBO
ERNA
Price
$2.30
$7.40
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.5K
2.9M
Earning Date
08-05-2025
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
337.04
31.29
EPS
0.02
N/A
Revenue
$9,469,000.00
$582,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$89.41
N/A
Revenue Growth
0.82
N/A
52 Week Low
$1.47
$0.13
52 Week High
$6.75
$8.49

Technical Indicators

Market Signals
Indicator
AMBO
ERNA
Relative Strength Index (RSI) 49.02 93.37
Support Level $1.88 $0.61
Resistance Level $2.50 N/A
Average True Range (ATR) 0.20 0.60
MACD -0.03 0.85
Stochastic Oscillator 51.32 87.19

Price Performance

Historical Comparison
AMBO
ERNA

About AMBO Ambow Education Holding Ltd.

Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.

About ERNA Eterna Therapeutics Inc.

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

Share on Social Networks: